179 related articles for article (PubMed ID: 31213506)
1. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology.
Yu JX; Craig AJ; Duffy ME; Villacorta-Martin C; Miguela V; Ruiz de Galarreta M; Scopton AP; Silber L; Maldonado AY; Rialdi A; Guccione E; Lujambio A; Villanueva A; Dar AC
Mol Cancer Ther; 2019 Sep; 18(9):1506-1519. PubMed ID: 31213506
[TBL] [Abstract][Full Text] [Related]
2. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same.
Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S
Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487
[TBL] [Abstract][Full Text] [Related]
4. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress.
Shen Z; Yin L; Zhou H; Ji X; Jiang C; Zhu X; He X
Cell Oncol (Dordr); 2021 Oct; 44(5):1035-1049. PubMed ID: 34176092
[TBL] [Abstract][Full Text] [Related]
6. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
8. Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.
Zhang Z; Miao L; Lv C; Sun H; Wei S; Wang B; Huang C; Jiao B
Cell Death Dis; 2013 Jun; 4(6):e657. PubMed ID: 23744357
[TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
10. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
[TBL] [Abstract][Full Text] [Related]
12. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
13. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
16. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways.
Lin Z; Li S; Guo P; Wang L; Zheng L; Yan Z; Chen X; Cheng Z; Yan H; Zheng C; Zhao C
Life Sci; 2019 Feb; 218():197-204. PubMed ID: 30582951
[TBL] [Abstract][Full Text] [Related]
17. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
18. RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.
Deng Q; Li KY; Chen H; Dai JH; Zhai YY; Wang Q; Li N; Wang YP; Han ZG
Hepatology; 2014 Feb; 59(2):518-30. PubMed ID: 23929653
[TBL] [Abstract][Full Text] [Related]
19. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Wang P; Jiang Z; Liu X; Yu K; Wang C; Li H; Zhong L
Cancer Med; 2020 Oct; 9(19):6972-6983. PubMed ID: 32779397
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]